How to Discuss the FDA’s Expedited EUA Process With Vaccine Hesitant Patients
March 9th 2021Pharmacy Times® interviewed Chad Landmon, JD, chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, on how to approach discussing the FDA’s expedited EUA process for COVID-19 vaccines with patients with concerns about the process.
Expert Says CAR T-Cell Therapies Could Make Cancer a Chronic Disease
March 8th 2021In a recent interview with Pharmacy Times, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, said the development of chimeric antigen receptor (CAR) T-cell therapies is a major step for the treatment of some cancers.
Pfizer COVID-19 Vaccine’s Updated Cold Storage Requirements Will Get More Doses in More Arms
March 3rd 2021Pharmacy Times® interviewed Farah Towfic, PharmD, MBA, the director and CEO of operations at US Pharmacopeia, on the FDA’s approval of the Pfizer and BioNTech COVID-19 vaccine’s updated cold storage requirements.
A Look at What’s Ahead in the Rapidly Growing Cell Therapy Landscape
February 26th 2021Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.
New Cancer Research Collaboration Seeks to Develop Targeted Radium Therapeutic
February 23rd 2021Pharmacy Times® interviewed J. David Robertson, PhD, director of University of Missouri Research Reactor, on a new collaboration with Advanced Accelerator Applications International to develop a targeted therapy for certain types of cancerous tumors.